Regulatory issues in human gene therapy

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Protection of human subjects is the ethical and legal responsibility of investigators conducting clinical trials. Public concerns regarding recombinant DNA technology led to additional levels of oversight which are unique to human gene therapy trials. The deaths of a normal volunteer and a gene therapy subject in the late 1990s led to an intensification of oversight with new initiatives that impact gene therapy as well as other clinical investigators. This paper will review the current oversight agencies and identify areas of evolving regulations that pose particular challenges to gene therapy investigators.

Original languageEnglish (US)
Pages (from-to)51-56
Number of pages6
JournalBlood Cells, Molecules, and Diseases
Volume31
Issue number1
DOIs
StatePublished - Jan 1 2003

Fingerprint

Genetic Therapy
Research Personnel
Recombinant DNA
Healthy Volunteers
Clinical Trials
Technology

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Hematology
  • Cell Biology

Cite this

Regulatory issues in human gene therapy. / Cornetta, Kenneth.

In: Blood Cells, Molecules, and Diseases, Vol. 31, No. 1, 01.01.2003, p. 51-56.

Research output: Contribution to journalArticle

@article{7d77ea6c8a03413b860babd28b8e0b85,
title = "Regulatory issues in human gene therapy",
abstract = "Protection of human subjects is the ethical and legal responsibility of investigators conducting clinical trials. Public concerns regarding recombinant DNA technology led to additional levels of oversight which are unique to human gene therapy trials. The deaths of a normal volunteer and a gene therapy subject in the late 1990s led to an intensification of oversight with new initiatives that impact gene therapy as well as other clinical investigators. This paper will review the current oversight agencies and identify areas of evolving regulations that pose particular challenges to gene therapy investigators.",
author = "Kenneth Cornetta",
year = "2003",
month = "1",
day = "1",
doi = "10.1016/S1079-9796(03)00059-7",
language = "English (US)",
volume = "31",
pages = "51--56",
journal = "Blood Cells, Molecules, and Diseases",
issn = "1079-9796",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Regulatory issues in human gene therapy

AU - Cornetta, Kenneth

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Protection of human subjects is the ethical and legal responsibility of investigators conducting clinical trials. Public concerns regarding recombinant DNA technology led to additional levels of oversight which are unique to human gene therapy trials. The deaths of a normal volunteer and a gene therapy subject in the late 1990s led to an intensification of oversight with new initiatives that impact gene therapy as well as other clinical investigators. This paper will review the current oversight agencies and identify areas of evolving regulations that pose particular challenges to gene therapy investigators.

AB - Protection of human subjects is the ethical and legal responsibility of investigators conducting clinical trials. Public concerns regarding recombinant DNA technology led to additional levels of oversight which are unique to human gene therapy trials. The deaths of a normal volunteer and a gene therapy subject in the late 1990s led to an intensification of oversight with new initiatives that impact gene therapy as well as other clinical investigators. This paper will review the current oversight agencies and identify areas of evolving regulations that pose particular challenges to gene therapy investigators.

UR - http://www.scopus.com/inward/record.url?scp=0038690170&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038690170&partnerID=8YFLogxK

U2 - 10.1016/S1079-9796(03)00059-7

DO - 10.1016/S1079-9796(03)00059-7

M3 - Article

C2 - 12850484

AN - SCOPUS:0038690170

VL - 31

SP - 51

EP - 56

JO - Blood Cells, Molecules, and Diseases

JF - Blood Cells, Molecules, and Diseases

SN - 1079-9796

IS - 1

ER -